Sarepta: What the Bulls Say
May 26, 2016 at 14:34 PM EDT
The response to Sarepta Therapeutics' ( SRPT ) gigantic jump following the FDA's delayed decision on its Duchenne muscular dystrophy treatment has been pretty bearish . But there are a couple of bulls out there. Baird's Brian Skorney and Neena Bitritto-Garg write that it's getting harder for the FDA to reject Sarepta's drug outright:
